ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical stage biopharmaceutical company developing pioneering treatments for renal and inflammatory diseases, is delighted to announce that its Co-Founder, Chairman, Chief Executive Officer, and President, Stephen C. Glover, will be a featured presenter at the Planet MicroCap Showcase 2023 in Las Vegas from April 25-27.
Don’t miss this unique opportunity to hear from the leader of a company creating groundbreaking therapies for medical conditions with high unmet needs.
ZyVersa is thrilled to be part of the Planet MicroCap Showcase 2023 to showcase the potential of its two platform technologies to create stockholder value.
Through the development of its two product candidates, Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, designed to reduce renal lipid accumulation and Inflammasome ASC Inhibitor IC 100, designed to block damaging inflammation associated with various inflammatory diseases, ZyVersa is poised to become a major player in the healthcare industry.
Gain insight into ZyVersa’s cutting-edge product pipeline by scheduling a one-on-one meeting with Mr. Glover through the conference portal. Uncover how the company’s unique offerings can provide you with the solutions you need for success.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is transforming healthcare for those with renal and inflammatory diseases. Through their advanced, proprietary technologies, the Company is developing innovative therapeutics to address significant unmet medical needs.
Their two leading drug candidates, Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100, are designed to tackle renal lipid accumulation and damaging inflammation respectively. By utilizing cutting-edge technology, ZyVersa is set to revolutionize the way these diseases are treated.